A First-in-Human (FIH), Open-Label, Phase Ia/Ib Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SON-DP in Participants With Relapsed/Metastatic Solid Tumors
Latest Information Update: 26 Apr 2024
At a glance
- Drugs SON DP (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Qurgen
Most Recent Events
- 22 Aug 2023 New trial record